Article Text

PDF
PWE-021 Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study
  1. K Klimova1,
  2. C Padilla2,
  3. A Gimenez-Manzorro3,
  4. A Hernando Alonso2
  1. 1GI Consequences of Treatment, Royal Marsden Hospital, London, UK
  2. 2Gastroenterology and Hepatology
  3. 3Pharmacy, Hospital General Universitario Gregorio Maranon, Madrid, Spain

Abstract

Introduction Gastrointestinal haemorrhage due to vascular malformations has a negative impact on patients’ quality of life and consumes an important quantity of resources.

Objective Analyse the cost-effectiveness of long-active releasing octreotide (OCT-LAR) in the treatment of gastrointestinal haemorrhage secondary to vascular malformations.

Method Retrospective study, including 19 pacients that were treated with mensual injections of OCTLAR between 2008–2013. The number of blood transfusions, haemoglobin levels, hospital admissions and possible side effects during the year before treatment and the year after the start of the treatment were assessed, and cost-effectiveness was analysed.

Results After the beginning of the treatment with OCTLAR, complete response was observed in 7 patients (36.8%), partial response in 7 patients (36.8%) and 5 patients (26.3%) continued to require admissions, blood transfusions and/or endoscopic treatment. We observed significant reduction in the length of admission per year (in days) before and after the start of the treatment (22.79 vs. 2.01 days, p < 0.0001) as well as in the number of blood transfusions administered (11.19 vs. 2.55 blood transfusions per year, p = 0.002). The mean haemoglobin levels increased from 6.9 g/dl to 10.62 g/dl (p < 0.0001). We observed reduction of costs of 61.5% between the two periods (from 36,072.35 to 13,867.57 €, p = 0.01). No side effects related to treatment were described.

Conclusion In conclusion, OCT-LAR seems to be a cost efficient and safe pharmacological treatment of gastrointestinal haemorrhage secondary to vascular malformations, mainly in patients in whom endoscopic or surgical treatment is contraindicated.

Disclosure of interest None Declared.

Reference

  1. Molina Infante J, Pérez Gallardo B, Hernández Alonso M, Mateos Rodríguez JM, Dueñas Sadornil C, Fernández Bermejo M. Octreotide long acting release for severe obscure gastrointestinal haemorrhage in elderly patients with serious comorbidities. Med Clin (Barc) 2009;133:667–70

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.